Intron a and Hepatic cirrhosis - a phase IV clinical study of FDA data

Summary:

Hepatic cirrhosis is reported as a side effect among people who take Intron a (interferon alfa-2b), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Rebetol, and have Hepatitis c.

The phase IV clinical study analyzes which people have Hepatic cirrhosis when taking Intron a. It is created by eHealthMe based on reports of 9,303 people who have side effects when taking Intron a from the FDA, and is updated regularly.

What is Intron a?

Intron a has active ingredients of interferon alfa-2b. eHealthMe is studying from 9,320 Intron a users. Check the latest studies of Intron a.

What is Hepatic cirrhosis?

Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue) is found to be associated with 1,192 drugs and 1,202 conditions by eHealthMe. Check the latest studies of Hepatic cirrhosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

9,303 people reported to have side effects when taking Intron a.
Among them, 41 people (0.44%) have Hepatic cirrhosis.

Among these 41 people:

How long have people been on Intron a when they have Hepatic cirrhosis? *

What is the gender of people who have Hepatic cirrhosis when taking Intron a? *

female: 28.21 %
male: 71.79 %

What is the age of people who have Hepatic cirrhosis when taking Intron a? *

What are other drugs people take besides Intron a? *

Rebetol: 13 people, 31.71%
Ribavirin: 6 people, 14.63%
Zoloft: 2 people, 4.88%
Ganciclovir: 2 people, 4.88%
Urso 250: 2 people, 4.88%
Halcion: 2 people, 4.88%
Amphotericin B: 2 people, 4.88%
Risperdal: 2 people, 4.88%
Ranitidine Hydrochloride: 2 people, 4.88%
Fluorouracil: 2 people, 4.88%

What are other side effects people have besides Hepatic cirrhosis? *

Hepatic Fibrosis (scarring process that represents the liver's response to injury): 5 people, 12.20%
Ascites (accumulation of fluid in the abdominal cavity): 5 people, 12.20%
Weight Decreased: 5 people, 12.20%
Malaise (a feeling of general discomfort or uneasiness): 5 people, 12.20%
Nausea (feeling of having an urge to vomit): 4 people, 9.76%
Hepatitis C: 4 people, 9.76%
Thrombocytopenia (decrease of platelets in blood): 4 people, 9.76%
Fatigue (feeling of tiredness): 4 people, 9.76%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 3 people, 7.32%
Hepatic Failure (liver failure): 3 people, 7.32%

What are the existing conditions these people have? *

Hepatitis C: 13 people, 31.71%
Hepatic Neoplasm Malignant (liver cancer): 2 people, 4.88%
Renal Cell Carcinoma Stage Unspecified (kidney cancer in unknown stage): 1 person, 2.44%
Quit Smoking: 1 person, 2.44%

* Approximation only. Some reports may have incomplete information.

Do you take Intron a and have Hepatic cirrhosis?

- Check whether Hepatic cirrhosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Intron a:

Intron a (9,320 reports)

Browse all side effects of Intron a:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatic cirrhosis:

Hepatic cirrhosis (1,192 drugs)

Browse all the conditions that are associated with Hepatic cirrhosis:

Hepatic cirrhosis (1,202 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on interferon alfa-2b (the active ingredients of Intron a) and Intron a (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.